MX2011005725A - Composicion farmaceutica de matriz. - Google Patents

Composicion farmaceutica de matriz.

Info

Publication number
MX2011005725A
MX2011005725A MX2011005725A MX2011005725A MX2011005725A MX 2011005725 A MX2011005725 A MX 2011005725A MX 2011005725 A MX2011005725 A MX 2011005725A MX 2011005725 A MX2011005725 A MX 2011005725A MX 2011005725 A MX2011005725 A MX 2011005725A
Authority
MX
Mexico
Prior art keywords
galantamine
pharmaceutical composition
polymer particles
amount
particle diameter
Prior art date
Application number
MX2011005725A
Other languages
English (en)
Spanish (es)
Inventor
Jae-Keol Rhee
Sung-Hoon Kam
Jae-Soon Ahn
Original Assignee
Hyundai Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyundai Pharm Co Ltd filed Critical Hyundai Pharm Co Ltd
Publication of MX2011005725A publication Critical patent/MX2011005725A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2011005725A 2010-01-26 2010-01-26 Composicion farmaceutica de matriz. MX2011005725A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2010/000469 WO2011093535A1 (ko) 2010-01-26 2010-01-26 갈란타민을 포함한 매트릭스 형태의 약학 조성물

Publications (1)

Publication Number Publication Date
MX2011005725A true MX2011005725A (es) 2011-08-30

Family

ID=44319504

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011005725A MX2011005725A (es) 2010-01-26 2010-01-26 Composicion farmaceutica de matriz.

Country Status (4)

Country Link
AR (1) AR080430A1 (pt)
BR (1) BRPI1005440A2 (pt)
MX (1) MX2011005725A (pt)
WO (1) WO2011093535A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
WO2007029081A1 (en) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Galantamine-containing controlled release oral dosage forms, processes for the preparation thereof and use for the manufacture of a medicament
US7955622B2 (en) * 2006-10-13 2011-06-07 Actavis Group Ptc Hf Controlled-release galantamine formulations
KR100782310B1 (ko) * 2007-03-22 2007-12-06 현대약품 주식회사 갈란타민 또는 이의 약학적으로 허용 가능한 염을 포함하는약학 조성물
EP2044933A1 (en) * 2007-10-05 2009-04-08 KRKA, D.D., Novo Mesto Multi particulate matrix system containing galantamine

Also Published As

Publication number Publication date
AR080430A1 (es) 2012-04-11
BRPI1005440A2 (pt) 2016-03-08
WO2011093535A1 (ko) 2011-08-04

Similar Documents

Publication Publication Date Title
KR100845660B1 (ko) 서방성 파라세타몰 조성물
JP2011126916A (ja) プラミペキソール又はその医薬品として許容される塩を含む放出が延長された錠剤調合物、その製造方法及びその使用
JP2005200400A (ja) ２４時間の臨床効果を有する徐放性トラマドール製剤
WO2009066315A2 (en) Sustained release compositions of trimetazidine and process for preparation thereof
JPH05213741A (ja) デプレニル／ｌ−ドーパ／カルビドーパ含有の医薬組成物
CA2182004C (en) Film coated tablet of paracetamol and domperidone
WO2010128525A2 (en) A formulation of ivabradine for treating the cardiovascular disease
WO2018108157A1 (zh) 一种瑞卡帕布口服缓控释药物组合物及其用途
JP2022500505A (ja) トリヘキシフェニジルを含む徐放性組成物
US20050118266A1 (en) Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
WO2006103551A1 (en) Controlled release formulations of oxycodone
US20150359795A1 (en) High drug load pharmaceutical compositions with controllable release rate and production methods thereof
WO2009027786A2 (en) Matrix dosage forms of varenicline
CA2781826A1 (en) Controlled release pharmaceutical compositions of galantamine
US20100272794A1 (en) Pharmaceutical composition of memantine
MX2011005725A (es) Composicion farmaceutica de matriz.
CA3069948C (en) A solid oral fixed dose composition comprising metformin, valsartan and atorvastatin
WO2019200512A1 (zh) 一种抗凝剂的速释药物制剂及其制备方法
KR100782310B1 (ko) 갈란타민 또는 이의 약학적으로 허용 가능한 염을 포함하는약학 조성물
AU2013366023A1 (en) Pharmaceutical formulation of n- [5- [2-(3,5-dimethoxyphenyl) ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl] benzamide
CA3048968A1 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
RU2603469C2 (ru) Таблетка с контролируемым высвобождением для перорального введения и способ ее приготовления
EP2736498B1 (en) Prolonged release pharmaceutical composition comprising galantamine and method for the preparation thereof
KR20120052080A (ko) 에페리손 함유 서방정 및 이의 제조 방법
WO2022138717A1 (ja) 経口固形製剤

Legal Events

Date Code Title Description
FA Abandonment or withdrawal